Sirs,

Thank you for your letter and for the opportunity to resubmit the manuscript MS: 1670463809132431 entitled “GENETIC VARIABILITY IN CYP3A4 AND CYP3A5 IN PRIMARY LIVER, GASTRIC AND COLORECTAL CANCER PATIENTS”.

We are thankful to reviewers and we agree with their comments. The manuscript was extensively revised according their suggestions and all concerns raised by the reviewers are addressed in the revised version of the manuscript. Changes are in red font in the revised version of the manuscript.

Reviewer Comments:

**Reviewer #1:**

The major problem with this paper is, that although quite significant numbers of patients are included per group, by breaking them down to the genetic variant groups, the numbers become very small indeed. Especially in the smallest group, stomach cancer, this leads rapidly to significance problems. For the present data the conclusions are correct, but it remains uncertain whether a relation would not pop up at larger numbers of patients.

The limitations of the study regarding this point have been highlighted in the discussion section (page 10).

On page 6 under “statistical analysis” the power of the study is roughly described. It would be preferable to explain the power calculations in more detail, especially with regard to the power in subgroups.

As requested, more details regarding power calculation were added to the revised version (pages 6 and 7).
Please, include method of DNA isolation (page 6)

The requested information was included in page 6.

There are a few small spelling mistakes.

Thank you for the observation. These mistakes have been corrected.

Reviewer #2:

No changes were required.

Additional changes:

In page 5 it was stated that participants gave written consent, and we added a reference where additional information on the subgroup of oldest control patients can be obtained.

English usage was corrected throughout the manuscript.

The manuscript was formatted according the checklist.

We hope that you consider the revised version of the manuscript adequate for publication in BMC Cancer.

We are looking forward to hear from you.

Yours sincerely,

Prof. José A.G. Agúndez
Department of Pharmacology
Medical School, University of Extremadura
Avda de Elvas s/n. 06071, Badajoz, Spain
Phone/Fax +34924289458, E-mail: jagundez@unex.es